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http://dx.doi.org/10.1016/j.pedneo.2
1875-9572/Copyrightª 2016, Taiwan P
NC-ND license (http://creativecommoBackground: A persistent increase in the number of lung fibroblasts (LFs) is found in the inter-
stitium of the lungs of infants with bronchopulmonary dysplasia (BPD), which leads to lung
fibrosis. P16 methylation plays an important role in the pathogenesis of BPD. 5-aza-20-deoxy-
cytidine (5-aza-CdR) is a major methyltransferase-specific inhibitor. This study investigated
the effects of 5-aza-CdR on LFs in vitro from a hyperoxia-induced lung fibrosis model in
newborn rats.
Methods: Methylation-specific polymerase chain reaction (PCR) and Western blotting were
performed to determine P16 gene methylation status and protein expression after LFs were
treated with 0 mmol/L, 0.5 mmol/L, 1.0 mmol/L, and 5.0 mmol/L 5-aza-CdR for 120 hours. Pro-
liferation was assessed by an MTT assay after LFs were treated with 0 mmol/L, 0.5 mmol/L,
1.0 mmol/L, and 5.0 mmol/L 5-aza-CdR for 24 hours, 48 hours, 72 hours, 96 hours, and 120 hours.
At the final time point, cells were also analyzed by flow cytometry to identify any change in
their cell cycle profiles.
Results: A methylated P16 gene promoter was detected in hyperoxia LFs. Following treatment
with 5-aza-CdR, partial methylation and demethylation was detected. The expression pro-
tein’s level of the P16 gene was significantly higher in the 5.0 mmol/L 5-aza-CdR-treated group
compared with that in the control group (p < 0.01). The cell growth rate at each tested time
point was lower in the 5-aza-CdR-treated group compared with that in the control group after
72 hours (p < 0.01). Flow cytometry revealed that the cells in the 1.0 mmol/L and 5.0 mmol/L 5-
aza-CdR-treated groups were apparently arrested in the G0/G1 phase and that the number of
cells in the S phase was significantly lower than the control group (p < 0.01).
Conclusion: 5-aza-CdR inhibits the growth of the LFs in hyperoxia-induced neonatal BPD ratsof Pediatrics, Shengjing Hospital of China Medical University, 36 Sanhao Street, Shenyang, Liaoning
(X. Xue).
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Bronchopulmonary dysplasia (BPD) is a chronic respiratory
disease that develops as a consequence of perinatal/
neonatal lung injury, and it is one of the most important
sequelae of premature birth.1,2 There are no safe and
effective preventive therapies because the mechanisms of
BPD are not known. However, new treatment strategies for
the prevention of BPD are promising. Impaired alveolari-
zation and widespread interstitial fibrosis have come to be
recognized as the prominent features of BPD.3,4 Fibroblasts
could play an important role in exacerbating the fibrotic
process of BPD in newborn animals by producing collagens
and extracellular matrix proteins.5,6 A persistent increase
in the number of fibroblasts is found both in the interstitium
and in the air spaces of lungs with BPD.7 Once BPD enters
the stage of pulmonary interstitial fibrosis, injury is irre-
versible. Determining how to prevent and alleviate the
proliferation of lung fibroblasts (LFs) effectively is the key
to BPD care.
The P16 gene is a specific inhibitor of cyclin-dependent
kinase 4 (CDK4) and CDK6 through inhibition of CDK4-
dependent phosphorylation of the retinoblastoma gene.8
The P16 gene plays an important role in cell-cycle regula-
tion by decelerating the progression of cells from the G1
phase to the S phase and then suppressing the cell cycle
progress.9,10 Reduction of P16 gene expression could in-
crease cell proliferation, and P16 gene expression could be
downregulated by DNA methylation. A recent study showed
that P16 methylation occurred in the lung tissue in rats
exposed to hyperoxia and that methylation levels gradually
increased and reached a peak in the period of maximum
lung fibrosis.11
At present, the primary drug for reversing DNA methyl-
ation is 5-aza-20-deoxycytidine (5-aza-CdR). The
methyltransferase-specific inhibitor 5-aza-CdR is a pyrimi-
dine analogue whose mechanism is to combine with DNA
during DNA replication, form covalent complexes with DNA
methyltransferase 1 (DNMT1), inhibit the enzyme’s methyl
transfer activity, produce low-methyl annihilator chains,
and reduce the hypermethylation of the gene promoter
region to recover gene activity. The present study aimed to
investigate the effect of different concentrations of 5-aza-
CdR on the demethylation of the P16 promoter and rees-
tablishment of P16 gene expression that consequently in-
hibits the growth of LFs. Our data may provide a new
strategy for the treatment of BPD.
2. Methods
2.1. Animals and oxygen exposure
This study was approved by the China Medical University
Animal Research Committee (Shenyang, China) and washao S, et al., 5-aza-20-deoxycytid
Neonatology (2016), http://dx.dperformed with newborn (12 hours old) Sprague-Dawley
rats whose mothers had been kept under standard
conditions.
Time-dated pregnant Sprague-Dawley rats were ob-
tained from the Center of Animal Experiments, China
Medical University. Rats were maintained on standard lab-
oratory food and water ad libitum and kept on a 12:12-hour
lightedark cycle. Within 12 hours of birth, pups with
nursing mothers were exposed to either normoxia [Fraction
of inspired oxygen (FiO2) Z 21%, n Z 47] or hyperoxia
(FiO2 Z 90%  2%, n Z 51). Nursing mothers were rotated
between normoxia and hyperoxia every 24 hours to avoid
oxygen toxicity in the mothers and to eliminate maternal
effects between groups.12
Animals were housed in standard cages placed inside
425-L capacity plexiglass isolation chambers, which
received humidified O2 or room air (30 L/min) at ambient
pressure. Preliminary continuous monitoring of the exper-
imental O2 chamber with an O2 sensor (OM-25 ME) showed
that it was stable (88e92%) under the conditions
described. The CO2 concentration was < 0.5%.
12 Survival
was recorded daily, and rats were exposed to oxygen for up
to 21 days.
2.2. Isolation and culture of LFs
All animals were sacrificed by an overdose of pentobarbital
sodium on postnatal Day 21. Lungs were finely minced and
digested in 0.2% trypsin and 0.016% deoxyribonuclease I in
minimum essential medium (MEM; Sigma Chemical Co., St.
Louis, MO, USA) for 2e4 hours at 37C. When digestion was
complete, the cell suspension was pipetted from the
minced lung preparation and filtered through sterile gauze
to remove particulate matter. Then, 10% fetal bovine serum
(FBS) was added to the filtered cell suspension to stop
further digestion. Cell pellets obtained by centrifugation
were then resuspended in MEM with 10% FBS, 10,000 U/mL
penicillin, and 10,000 mg/mL streptomycin (Sigma Chemical
Co.). The cells were incubated in 25-cm2 plastic culture
flasks overnight. The medium and nonadherent cells were
removed, and fresh MEM with 10% FBS was added. Fibro-
blast predominance was > 95%, as confirmed by immuno-
cytochemical staining for vimentin.13 When passaged, cells
were seeded into 150-cm2 culture flasks at a density of
2.5  105 cells/flask or 5  105 cells/flask. All experiments
were performed on fibroblasts of passage number 2e4.7
2.3. 5-Aza-CdR treatment
LFs (1  106) in six-well plates were treated with various
concentrations of freshly prepared 5-aza-CdR (0.5 mmol/L,
1.0 mmol/L, and 5.0 mmol/L) in DMSO (Sigma Chemical Co.)
the next day. The medium was changed 24 hours after
treatment and every 5 days thereafter. At the end ofine Inhibits the Proliferation of Lung Fibroblasts in Neonatal Rats
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medium without 5-aza-CdR, the cells were cultured for an
additional 24 hours, and then they were harvested for use
in subsequent assays. Control cultures were treated under
similar experimental conditions in the absence of 5-aza-
CdR.
2.4. Methylation-specific polymerase chain
reaction
The cells of different groups were collected for
methylation-specific polymerase chain reaction (PCR) at
120 hours postincubation. The DNA from the cells was
extracted using the ZR Genomic DNA II kit (Zymo Research
Corporation, Irvine, CA, USA) as recommended by the
manufacturer. Bisulfite modification of the genomic DNA
was performed using the EZ DNA Methylation-Gold kit (Zymo
Research Corporation) according to the manufacturer’s in-
structions. The PCR amplification was performed using P16
promoter gene fragment-specific primers for methylated or
unmethylated DNA (Sangon Biotech Co., Ltd., Shanghai,
China). The primers used for unmethylated P16 were as
follows: sense, 50-TTTTTGGTGTTAAAGGGTGGTGTACT-30,
and antisense, 50-CACAAA AACCCTCACTCACAACAA-30, which
yielded a fragment of 132 base pairs. The primers used for
methylated P16 were as follows: sense, 50-
GTGTTAAAGGGCGGCGTAGC-30, and antisense, 50-AAA
ACCCTCACTCGCGACGA-30, which yielded a PCR product of
122 base pairs. PCR was performed under the following
conditions: 95C for 4 minutes, 94C for 25 seconds, 62C for
25 seconds, and 72C for 30 seconds for 25 cycles; and 72C
for 5 minutes. The CpGenome universal methylated DNA
(Millipore Corporation, Billerica, MA, USA) was used as a
control for the methylated DNA. The PCR-amplified prod-
ucts were separated by electrophoresis on a 2% agarose gel
and visualized by ethidium bromide staining under ultravi-
olet light. Images were then captured.
2.5. Western blot assay
The cells of different groups were collected and washed
with phosphate buffered saline, and then protein was
extracted with RIPA Lysis Buffer (Beyotime Biotechnology,
Shanghai, China) according to the manufacturer’s in-
structions. Then, 30 mg of protein was subjected to sodium
dodecyl sulfate-polyacrylamide gel (8%) electrophoresis
followed by electrotransfer onto a polyvinylidenedifluoride
membrane (Immobilon-P; Millipore Corporation). This
membrane was blocked for 2 hours with 5% skim milk in
Tris-buffered saline/Tween 0.05% and then incubated with
an anti-P16 primary antibody (1:1000, Santa Cruz Biotech-
nology, Inc., CA, USA) and antiactin (1:1000, Cell signaling,
Boston, MA, USA) overnight at 4C. The membrane was
washed three times with Tris-buffered saline/Tween 0.05%
at room temperature for 10 minutes and treated with a
peroxide-conjugated secondary antibody (1:5000, Beyo-
time Biotechnology) for 2 hours. Proteins in the membrane
were detected by the enhanced chemiluminescence system
(ECL advance; Amersham Biosciences, USA), and the image
was recorded and analyzed using the BIO-RAD ChemiDoc
XRS system (BIO-RAD, CA, USA).Please cite this article in press as: Zhao S, et al., 5-aza-20-deoxycytid
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Cells were plated in quadruplicate at 1  103 cells per well
in a 96-well plate, cultured as described above and treated
in the presence of increasing concentrations of 5-aza-CdR
for 5 days. Twenty microliters of 5 mg/mL 3-(4,5-dimethy-
lthiazol-2-yl)-2,5-diphenyltetrazolium (MTT; Amresco, Ari-
zona, PA, USA) was then added into each well, and the cells
were cultured at 37C for an additional 4e6 hours. After
culture, the supernatant was discarded, and the resulting
formazan crystals were solubilized by adding 150 mL of
DMSO to each well. The optical density level under 570 nm
was measured, and the percentage of cell viability was
calculated using the following formula:
percentage of cell viabilityZ (absorbance of experimental
well  absorbance of blank)/(absorbance of untreated
control well  absorbance of blank)  100%. (1)2.7. Cell cycle test
The cell cycle phase distribution was evaluated using flow
cytometry. Cells were seeded into a six-well plate at a
density of 1  106 cells per well. They were incubated and
allowed to grow to 70e80% confluence, and then the cells
were treated with 5-aza-CdR and incubated for an addi-
tional 120 hours. After being harvested by trypsin release,
the cells were washed twice with phosphate buffered sa-
line and permeabilized with 70% ethanol overnight. On the
next day, the ethanol was discarded, and the cells were
incubated for 15e20 minutes at 37C with 1 mL of a PI
solution (0.1% trixton-100, 50 mg of PI and 200 mg of RNase
A). The distribution of the cell cycle phases was deter-
mined with a flow cytometer (Becton, Dickinson and
Company, NJ, USA).
2.8. Statistical analysis
All experiments were repeated five times with similar re-
sults, and data is presented as the mean  standard devi-
ation. Statistical significance was determined by one-way
analysis of variance followed by Dunnett’s test. A value of
p < 0.05 was considered statistically significant. All statis-
tical analyses were performed using the statistical software
SPSS 17.0 (SPSS Inc., Chicago, IL, USA).
3. Results
No pups died in normoxic groups throughout the study
period. In comparison with normoxia rat pups, the hyper-
oxic groups had markedly worse survival (normoxia, 100%;
hyperoxia, 19.61%; p < 0.01).
3.1. P16 methylation in LFs and 5-aza-CdR can
affect P16 gene methylation status
We found that the P16 gene was mostly methylated in LFs
in the hyperoxia group. No methylation was observed in
the normoxia group. Partial methylation was observed atine Inhibits the Proliferation of Lung Fibroblasts in Neonatal Rats
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demethylation was observed at 5.0 mmol/L, demon-
strating a concentration-dependent effect (Figures 1A
and 1B).A B C D
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P16 gene at the protein level
Western blot analysis revealed that the expression protein’s
level of the P16 gene in the control group was
0.368  0.064, whereas those in the 5-aza-CdR treatment
groups were 0.43  0.065, 0.466  0.070, and 0.63  0.091
when the drug dosage was 0.5 mmol/L, 1.0 mmol/L, and
5.0 mmol/L, respectively. Only 5-aza-CdR at 5.0 mmol/L was
statistically significant by comparison with the control
group (p < 0.01; Figure 2). We found that 5.0 mmol/L of 5-
aza-CdR could reestablish P16 gene expression in LFs in the
hyperoxia group.Figure 2 Changes in P16 expression in LFs following treat-
ment with 5-aza-CdR (n Z 5). A Z control group;
B Z 0.5 mmol/L 5-aza-CdR; C Z 1.0 mmol/L 5-aza-CdR;
D Z 5.0 mmol/L 5-aza-CdR. *p < 0.01.
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CdR-treated LFs
We tested the effect of 5-aza-CdR on the viability of LFs
using MTT assays. The MTT assay showed that when the cells
were cultured for 120 hours then treated with 5-aza-CdR;
there was a remarkable inhibiting action after 72 hours of
treatment (Figure 3). The cytostatic effect increased with
the increase of the drug dosage in a dose-dependent
manner. We found that 5-aza-CdR effectively suppressed
LF growth and proliferation in a dose-dependent manner
(Figure 3).A
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Figure 1 (A) The methylation state of the P16 gene in LFs;
(B) Changes in the methylation state of the P16 gene in LFs
following treatment with 5-aza-CdR. A,B Z normoxia group;
C,DZ hyperoxia group; E Z control group; FZ 0.5 mmol/L 5-
aza-CdR; G Z 1.0 mmol/L 5-aza-CdR; H Z 5.0 mmol/L 5-aza-
CdR; M Z methylated; U Z unmethylated.
0 24 48 72 96 120 144
0.0
Figure 3 Growth curve of 5-aza-CdR-treated LFs (n Z 5).
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aza-CdR-treated LFs
To examine the cellular event induced by 5-aza-CdR more
closely, we evaluated the cell cycle distribution of LFs
treated with 5-aza-CdR at different concentrations. Flow
cytometry revealed that the cells in the 1.0 mmol/L and
5.0 mmol/L 5-aza-CdR-treated groups were apparently
arrested in the G0/G1 phase (1.0 mmol/L, p < 0.05 and
5.0 mmol/L, p < 0.01; Table 1) and that the number of cells
in the S phase (1.0 mmol/L and 5.0 mmol/L, p < 0.01; Table
1) was significantly lower than in the control group.
4. Discussion
Hyperoxia is a significant cause of lung injury and contrib-
utes to the pathogenesis of BPD.14,15 The hallmark features
of BPD are a decreased number of alveoli, increased vari-
ability in alveolar size, and lung interstitial fibrosis.3,16
There is evidence from animal models that exposure of
the developing lung to hyperoxia leads to the development
of a simplified lung structure that resembles human BPD.15ine Inhibits the Proliferation of Lung Fibroblasts in Neonatal Rats
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Table 1 Effect of 5-aza-CdR on cell-cycle distribution (%,
n Z 5).
Groups G0/G1 S G2/M
Control 72.17  1.89 20.86  1.98 6.97  1.87
0.5 mmol/L 75.36  3.26 17.06  2.36 7.59  1.67
1.0 mmol/L 79.09  2.85* 12.65  2.24** 8.26  1.05
5.0 mmol/L 89.44  2.97** 5.53  1.88** 5.04  1.25
*p < 0.05 compared with the control group.
**p < 0.01 compared with the control group.
hyperoxia
P16 gene                   P16 methylation           
5-aza-CdR
CDK4/CDK6               CDK4/CDK6 
RB                  phosphorylation of RB
G1/S                   G1/S 
Normal cell growth         Abnormal cell proliferation 
Figure 4 The effects of 5-aza-CdR on P16 gene expression
and cell proliferation.
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the method of Warner et al,17 which thoroughly examines
the progression of acute and chronic changes which occur in
the lungs of full-time newborn rats during prolonged
(28 days) exposure to hyperoxia. It showed significant lung
interstitial fibrosis in rats exposed to hyperoxia for 21 days.
Our initial findings showed a significant decrease in P16
gene expression in lung tissues of rats exposed to hyper-
oxia, and high DNA methylation at the promoter region is
the main reason for inactivation of P16 gene transcription.
Hyperoxia induced abnormal P16 methylation in the post-
exposure period. As exposure extended, the methylation
level gradually increased and reached a peak in the period
of maximum lung fibrosis.11 DNA hypermethylation may
decrease or block the expression of P16 gene, cause it to
lose function, and promote abnormal cell proliferation.11
This may result in unrestricted cell growth and ultimately
lead to lung interstitial fibrosis.
The process by which methylation regulates gene
expression is reversible because methylation status can be
reversed by methyltransferase inhibitor.18 Therefore, the
normal regulation of cells is restored by recovering the
expression of unmutated genes to achieve the purpose of
the treatment. Normal human cell genes are not controlled
by CpG island methylation. Therefore, the inhibition of
methylation does not affect the expression of genes in
normal cells. At present, the primary drug for reversing DNA
methylation is 5-aza-CdR.18 The methyltransferase-specific
inhibitor 5-aza-CdR is a pyrimidine analogue whose mech-
anism is to combine with DNA during DNA replication, form
covalent complexes with DNMT1, inhibit the enzyme’s
methyl transfer activity, produce low-methyl annihilator
chains, and reduce the hypermethylation of the gene pro-
moter region to recover gene activity.19
The study first showed that abnormal methylation of the
P16 gene promoter by hyperoxia contributed to the in-
crease of the proliferation of LFs. We then used this
hyperoxia-induced BPD mouse model to investigate the
activity of 5-aza-CdR in inhibiting the growth and prolifer-
ation of LFs. This study also evaluated the effects of 5-aza-
CdR on the demethylation and reactivation of expression of
the P16 gene. The present study revealed that the LFs were
in a state of hypermethylation after hyperoxia exposure for
21 days and no methylation was observed in LFs after air
exposure. At 0.5 mmol/L and 1 mmol/L 5-aza-CdR treatment
for 5 days, the P16 gene promoter was only partially
methylated. At 5 mmol/L 5-aza-CdR treatment for 5 days,
the P16 gene promoter was completely methylated, the
cells were in a demethylated state, and the silenced P16
gene was strongly reexpressed at the protein level. ThisPlease cite this article in press as: Zhao S, et al., 5-aza-20-deoxycytid
Exposed to Hyperoxia, Pediatrics and Neonatology (2016), http://dx.dmay affect P16 gene expression without causing any change
to the gene sequence. Due to demethylation, P16 gene
expression increased. The P16 gene is an important regu-
lating factor of the cell cycle, and it negatively regulates
the G1/S transition of the cell cycle. Therefore, loss of P16
gene function should potentiate the transition of cells into
the S phase and increase cellular proliferation.20 A cell
growth curve experiment showed a decrease in the growth
rate of LFs when treated with 5-aza-CdR at a low concen-
tration of 0.5 mmol/L and this led to significant growth and
proliferation suppression at 5 mmol/L on Days 3e5. These
data suggested that P16 demethylation and reactivation
might be responsible for the cell growth inhibition induced
by 5-aza-CdR. It also supports the observation that the P16
gene is epigenetically silenced via promoter hyper-
methylation in LFs of BPD. To examine the cellular event
induced by 5-aza-CdR more closely, we evaluated the cell
cycle distribution of LFs treated with 5-aza-CdR at different
concentrations. Flow cytometry showed that the number of
cells in G0/G1 significantly increased and in S phase
significantly decreased following treatment with 5-aza-CdR
at a concentration of 1 mmol/L and 5 mmol/L for 5 days,
indicating that the LFs were arrested in the G0/G1 phase
and the growth inhibitory effect of the P16 gene might work
by affecting the cell cycle following demethylation.
The data clearly demonstrates that DNA hyper-
methylation of the P16 gene, a well-known cell cycle in-
hibitor, is at least partly responsible for the downregulation
of P16 gene expression and thus contributes to hyperoxia-
enhanced cell proliferation. Treatment of the hyperoxia-
exposed LFs with 5-aza-CdR resulted in the loss of
methyl-cytosine in the CpG island of the P16 gene, the
recovery of P16 gene expression, and suppression of the
growth and proliferation of LFs by restraining cells at G0/
G1 (Figure 4). These results suggested that methylation
inhibition might be a potential approach in the prevention
and treatment of BPD. The Federal Drug Administration has
approved 5-aza-CdR for the treatment of myelodysplastic
syndrome, but 5-aza-CdR is a cytotoxic drug with some side
effects when use at toxic doses, such as leucopenia,
thrombocytopenia, and weight loss.21 Clinical efficacy,
tolerability in vivo and the best compatibility dose need
further research, before it can be used in BPD treatment.ine Inhibits the Proliferation of Lung Fibroblasts in Neonatal Rats
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